People taking retatrutide, a drug being developed by Eli Lilly, lost an average of more than 70 pounds, or 28.3% of their bodyweight, over the course of 80 weeks, according to the company's preliminary report of clinical trial results
This documentation enables retrospective analysis if you notice any unexpected changes in your data patterns
This means reported events may vary depending on the trial dose group and escalation design
Navigating it holisticallyworking with doctors, PTs, and support groupscan yield better results and help everyone find what works
* Excludes Quebec, Nova Scotia, Nunavut and the Northwest Territories The information presented here is for educational purposes and is not meant to replace the advice from your medical professional